Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Primary Biliary Cholangitis Therapeutics Market: By Type: OCALIVA, Ursodiol, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; SWOT Analysis; Porter’s Five Forces Analysis; EMR’s Key Indicators for Demand; Competitive Landscape; Industry Events and Developments

Global Primary Biliary Cholangitis Therapeutics Market Outlook

The global primary biliary cholangitis therapeutics market is expected to grow at a CAGR of about 10.5% in the forecast period of 2022-2027. One of the key drivers for the industry growth is the increasing awareness campaigns to mitigate more complications in the primary biliary cholangitis indicator.

 

Global Primary Biliary Cholangitis Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Primary biliary cholangitis refers to a rare chronic disease of the liver, formerly referred to as primary biliary cirrhosis, mainly characterized by the degradation of the biliary ducts, which contain bile acid from the skin. Even though the root cause of the disease has still not been established, worldwide work has shown that the disorder is autoimmune in nature. The progression of this disease contributes to the destructive deposition of bile acid, which causes serious liver damage. The disease mainly affects middle-aged women. The lack of a conclusive treatment for primary biliary cholangitis (PBC) offers an incredibly lucrative business opportunity.

 

Global Primary Biliary Cholangitis Therapeutics Market by Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry can be broadly categorised based on its type into:

  • OCALIVA
  • Ursodiol
  • Others

The EMR report looks into the regional markets of primary biliary cholangitis therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Primary Biliary Cholangitis Therapeutics Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The increasing awareness campaigns aimed at reducing any more complications in the primary indication of cholangitis are among the main drivers of the industry growth. The asymptomatic nature of the condition, in most cases, leads to a delay in diagnosis. Moreover, the majority of the population is not aware of the signs of the disease. Many sellers took advantage of this and began to organize awareness campaigns. Many non-profit organizations also run prevention campaigns and fund research into new disease therapies. Such factors will expand the sales of primary biliary cholangitis therapies and enable the market to grow.

Regenerative therapy study gains traction as an experimental liver transplant phase triggers a problem for patients following surgery. However, owing to the chronic nature of the disease, there is currently no treatment for the symptom other than a liver transplant. It allows researchers to perform a stem cell transplantation test that can replace those cells destroyed in the bile duct. This current research should have a positive effect on the overall growth of the market.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global primary biliary cholangitis therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Abbott Laboratories (NYSE: ABT)
  • Allergan Plc 
  • Eli Lilly and Co. 
  • Intercept Pharmaceuticals Inc. 
  • Takeda Pharmaceutical Co. Ltd. 
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Region
Breakup by Type OCALIVA, Ursodiol, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Intercept Pharmaceuticals, Inc., Novartis AG, Glenmark Pharmaceuticals, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Primary Biliary Cholangitis Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Primary Biliary Cholangitis Therapeutics Historical Market (2017-2021) 
    8.3    Global Primary Biliary Cholangitis Therapeutics Market Forecast (2022-2027)
    8.4    Global Primary Biliary Cholangitis Therapeutics Market by Type
        8.4.1    OCALIVA
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Ursodiol
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Others
    8.5    Global Primary Biliary Cholangitis Therapeutics Market by Region
        8.5.1    Market Share
            8.5.1.1    North America
            8.5.1.2    Europe
            8.5.1.3    Asia Pacific
            8.5.1.4    Latin America
            8.5.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Intercept Pharmaceuticals, Inc.
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Novartis AG
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Glenmark Pharmaceuticals
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Others
13    Industry Events and Developments


List of Figures and Tables

1.    Global Primary Biliary Cholangitis Therapeutics Market: Key Industry Highlights, 2016 and 2026
2.    Global Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Type (USD Billion), 2017-2021
3.    Global Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Type (USD Billion), 2022-2027
4.    Global Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
5.    Global Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
6.    North America Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
7.    North America Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
8.    Europe Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
9.    Europe Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
10.    Asia Pacific Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    Asia Pacific Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Latin America Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Latin America Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Middle East and Africa Primary Biliary Cholangitis Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Middle East and Africa Primary Biliary Cholangitis Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Global Primary Biliary Cholangitis Therapeutics Market Structure

Key Questions Answered in the Report

The global primary biliary cholangitis therapeutics market is projected to grow at a CAGR of 10.5% between 2021 and 2026.

The major drivers of the industry, such as the increasing awareness campaigns aimed at reducing any more complications, asymptomatic nature of the condition, unawareness of the symptoms of the disease among the population, and increasing funding of research into new disease therapies, are all expected to aid the market growth.

The key market trend guiding the growth of the primary biliary cholangitis therapeutics industry include the ongoing research to perform a stem cell transplantation test that can replace those cells destroyed in the bile duct.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

OCALIVA and ursodiol, among others, are the major types of primary biliary cholangitis therapeutics in the industry.

The major players in the industry are Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd., among others.

Analyst Review

The global primary biliary cholangitis therapeutics market is being driven by the growing awareness campaigns. Aided by the increased research funding in the industry, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 10.5%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the industry can be segmented into OCALIVA, ursodiol, and others. The major regional markets for primary biliary cholangitis therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER